PubMed Health⌕ Search

Biomedical subjects

Pollen K F Yeung

Publications and source records attributed to Pollen K F Yeung.

5 recordsLinked to original sources
PubMed2006

Exercise hemodynamic and neurohormone responses as sensitive biomarkers for diltiazem in rats.

PURPOSE: To investigate the potential of exercise hemodyanamic and neurohormone variables as sensitive biomarkers for pre-clinical evaluation of diltiazem (DTZ). METHODS: Sprague Dawley (SD) rats were randomly divided into 3 groups (n = 6 - 8 each), and each group received DTZ 10 mg/kg twice daily for 5 doses or saline followed by a treadmill exercise protocol for 7 min with speed set at 7 m/min at 3 % grade. The 3rd group received saline but no exercise. RESULTS: Exercise increased SBP from 108 +/- 2 to 131 +/- 3 mmHg, and HR from 437 +/- 6 to 503 +/- 6 bpm, and plasma epinephrine concentrations from 2.0 +/- 0.6 to 5.8 +/- 1.7 ng/mL in control rats (p < 0.05 for all variables), but had no significant effect on DBP (81 +/- 5 vs 87 +/- 6 mmHg) and plasma norepinephrine concentrations (1.5 +/- 0.2 vs 3.9 +/- 0.4 ng/mL). The hemodynamic responses to exercise were significantly attenuated by DTZ (p < 0.05), but the effect on neurohormone response was minimal (p > 0.05). CONCLUSION: Exercise hemodynamic and neurohormone responses are sensitive biomarkers which could be used for safety and efficacy evaluation of DTZ and perhaps also other calcium antagonists in pre-clinical animal models.

Animals↗
PubMed2005

Biomarker World Congress 2005.

This report covers some of the many excellent talks, and a selected number of posters, that were presented at this conference. It includes several emerging issues in biomarker development and the question of how biomarker science can drive targeted drug discovery and development and form a scientific basis for personalized medicine. Although relatively small, the meeting provided a good opportunity for business networking, particularly for those involved in the development and regulation of medical diagnostics and biopharmaceuticals.

Animals↗
PubMed2004

DP-b99 (D-Pharm).

DP-b99 is a derivative of the calcium chelator BAPTA that is under development as a neuroprotectant for the potential treatment of stroke, head trauma and neurological damage associated with coronary artery bypass graft. By March 2003, phase II clinical trials in acute stroke and traumatic brain injury were ongoing.

Animals↗
PubMed2003

Technology evaluation: GEM-231, Hybridon.

GEM-231 (HYBO-165) is an 18mer hybrid oligonucleotide under development by Hybridon for the potential treatment of cancer. Phase I/II dose-escalation trials of GEM-231 in combination with paclitaxel and docetaxel were ongoing in March 2002. At this time, a phase I/II trial of GEM-231 in combination with irinotecan (CPT-11) was initiated in patients with solid tumors. As of February 2003, Hybridon planned to initiate phase II trials in 2003.

Animals↗